CDNA · NASDAQ · STOCK
CareDx (CDNA) Stock Analysis
$63.64
52W $14.03 – $72.51
63/100
$3.29B
29.6
2.38
Is CDNA Bullish or Bearish?
Bullish.
Innellis AI committee rates CareDx, Inc (CDNA) Buy with a composite score of 63/100
, based on 6 analysts with 83% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.05 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.95 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is revenue growing 34.4% yoy -- genuine top-line momentum. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- ROE of 32.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 227.0% YoY — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 37.5% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
63/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 15%
of 192 Healthcare peers
Value Analyst
bullish
60
/ 100 · High confidence
Classic value case: cheap on multiples with earnings power to back it up
+ ROE of 32.8% shows genuine earnings power backing the valuation
− P/E of 29.0 is moderate-to-rich
Growth Analyst
bullish
68
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 34.4% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 37.5% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 4 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 62.5 to 63.0.
- New bearish signals: 3 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
55.5
Neutral
MACD Histogram
-0.334
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.65
Inside Bands
Price vs Moving Averages
EMA 9
$63.61
Above
EMA 21
$60.40
Above
EMA 50
$53.07
Above
EMA 200
$34.89
Above
Fundamental Analysis
Valuation
49
Growth
51
Profitability
50
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
29.6×
P/B Ratio
7.70×
PEG Ratio
-0.03
Dividend Yield
0.00%
52W High
$72.51
52W Low
$14.03
Quality & Growth
ROE
-704.5%
ROA
-516.8%
Gross Margin
7058.2%
Operating Margin
-92.4%
Revenue Growth YoY
—
Debt / Equity
0.05
AI Fundamental Assessment
P/E ratio of 29.6 (moderate relative to a 15-40x range); Price-to-book of 7.7x; PEG ratio of -0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -7.0%; Return on assets of -5.2%; Net margin of 24.2%; Gross margin of 70.6%; Current ratio of 4.58 (healthy short-term liquidity); Debt-to-equity of 0.05; Free cash flow per share is positive (1.65); Most recent quarter beat estimates by 55.8%; 2 consecutive earnings beats; EPS growth decelerating (+183.3% -> +8.8% QoQ); Analyst estimates falling over recent quarters
Get the Full CDNA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →